These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Primary biliary cirrhosis in the era of liver transplantation. Raczyńska J; Habior A; Pączek L; Foroncewicz B; Pawełas A; Mucha K Ann Transplant; 2014 Sep; 19():488-93. PubMed ID: 25262831 [TBL] [Abstract][Full Text] [Related]
4. Trends in liver transplantation for primary biliary cholangitis in Europe over the past three decades. Harms MH; Janssen QP; Adam R; Duvoux C; Mirza D; Hidalgo E; Watson C; Wigmore SJ; Pinzani M; Isoniemi H; Pratschke J; Zieniewicz K; Klempnauer JL; Bennet W; Karam V; van Buuren HR; Hansen BE; Metselaar HJ; Aliment Pharmacol Ther; 2019 Feb; 49(3):285-295. PubMed ID: 30561112 [TBL] [Abstract][Full Text] [Related]
5. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Charatcharoenwitthaya P; Pimentel S; Talwalkar JA; Enders FT; Lindor KD; Krom RA; Wiesner RH Liver Transpl; 2007 Sep; 13(9):1236-45. PubMed ID: 17763401 [TBL] [Abstract][Full Text] [Related]
6. Current Status of Liver Transplantation for Primary Biliary Cholangitis. Aguilar MT; Carey EJ Clin Liver Dis; 2018 Aug; 22(3):613-624. PubMed ID: 30259857 [TBL] [Abstract][Full Text] [Related]
7. A Comparison of Prognostic Scores (Mayo, UK-PBC, and GLOBE) in Primary Biliary Cholangitis. Goet JC; Murillo Perez CF; Harms MH; Floreani A; Cazzagon N; Bruns T; Prechter F; Dalekos GN; Verhelst X; Gatselis NK; Lindor KD; Lammers WJ; Gulamhusein A; Reig A; Carbone M; Nevens F; Hirschfield GM; van der Meer AJ; van Buuren HR; Hansen BE; Parés A; Am J Gastroenterol; 2021 Jul; 116(7):1514-1522. PubMed ID: 33941746 [TBL] [Abstract][Full Text] [Related]
8. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. Harms MH; van Buuren HR; Corpechot C; Thorburn D; Janssen HLA; Lindor KD; Hirschfield GM; Parés A; Floreani A; Mayo MJ; Invernizzi P; Battezzati PM; Nevens F; Ponsioen CY; Mason AL; Kowdley KV; Lammers WJ; Hansen BE; van der Meer AJ J Hepatol; 2019 Aug; 71(2):357-365. PubMed ID: 30980847 [TBL] [Abstract][Full Text] [Related]
9. Effect of pretransplantation ursodeoxycholic acid therapy on the outcome of liver transplantation in patients with primary biliary cirrhosis. Heathcote EJ; Stone J; Cauch-Dudek K; Poupon R; Chazouilleres O; Lindor KD; Petz J; Dickson ER; Poupon RE Liver Transpl Surg; 1999 Jul; 5(4):269-74. PubMed ID: 10388499 [TBL] [Abstract][Full Text] [Related]
10. Effect of S-adenosyl-L-methionine on liver biochemistry and quality of life in patients with primary biliary cholangitis treated with ursodeoxycholic acid. A prospective, open label pilot study. Wunsch E; Raszeja-Wyszomirska J; Barbier O; Milkiewicz M; Krawczyk M; Milkiewicz P J Gastrointestin Liver Dis; 2018 Sep; 27(3):273-279. PubMed ID: 30240471 [TBL] [Abstract][Full Text] [Related]
11. Risk factors for hepatic decompensation in patients with primary biliary cirrhosis. Shi TY; Zhang LN; Chen H; Wang L; Shen M; Zhang X; Zhang FC World J Gastroenterol; 2013 Feb; 19(7):1111-8. PubMed ID: 23467321 [TBL] [Abstract][Full Text] [Related]
13. Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response. Reig A; Sesé P; Parés A Am J Gastroenterol; 2018 Jan; 113(1):49-55. PubMed ID: 29016567 [TBL] [Abstract][Full Text] [Related]
14. Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis. Efe C; Taşçilar K; Henriksson I; Lytvyak E; Alalkim F; Trivedi H; Eren F; Eliasson J; Beretta-Piccoli BT; Fischer J; Calişkan AR; Chayanupatkul M; Coppo C; Ytting H; Purnak T; Muratori L; Werner M; Muratori P; Rorsman F; Önnerhag K; Günşar F; Nilsson E; Heurgué-Berlot A; Güzelbulut F; Demir N; Gönen C; Semela D; Aladağ M; Kiyici M; Schiano TD; Montano-Loza AJ; Berg T; Ozaslan E; Yoshida EM; Bonder A; Marschall HU; Wahlin S Am J Gastroenterol; 2019 Jul; 114(7):1101-1108. PubMed ID: 31241547 [TBL] [Abstract][Full Text] [Related]
15. Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence. Bosch A; Dumortier J; Maucort-Boulch D; Scoazec JY; Wendum D; Conti F; Morard I; Rubbia-Brandt L; Terris B; Radenne S; Abenavoli L; Poupon R; Chazouillères O; Calmus Y; Boillot O; Giostra E; Corpechot C J Hepatol; 2015 Dec; 63(6):1449-58. PubMed ID: 26282232 [TBL] [Abstract][Full Text] [Related]
16. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Kuiper EM; Hansen BE; de Vries RA; den Ouden-Muller JW; van Ditzhuijsen TJ; Haagsma EB; Houben MH; Witteman BJ; van Erpecum KJ; van Buuren HR; Gastroenterology; 2009 Apr; 136(4):1281-7. PubMed ID: 19208346 [TBL] [Abstract][Full Text] [Related]
17. The effect of liver transplantation on fatigue in patients with primary biliary cirrhosis: a prospective study. Carbone M; Bufton S; Monaco A; Griffiths L; Jones DE; Neuberger JM J Hepatol; 2013 Sep; 59(3):490-4. PubMed ID: 23628322 [TBL] [Abstract][Full Text] [Related]
18. Prognosis of 732 ursodeoxycholic acid-treated patients with primary biliary cholangitis: A single center follow-up study from China. Chen S; Duan W; Li M; Li S; Lv T; Tian Q; Wang Q; Wu X; Zhao X; Wang X; Wang Y; Kong Y; Ma H; Ou X; You H; Jia J J Gastroenterol Hepatol; 2019 Jul; 34(7):1236-1241. PubMed ID: 30365184 [TBL] [Abstract][Full Text] [Related]